Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)

ConditionChronic Graft Vs. Host Disease

Trial statusAvailable

Trial phaseNot listed

Trial typeExpanded Access

Biological sexNot listed

AgeNot listed

SponsorIncyte Corporation

About this trial

This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

axatilimab
Drug
Treatment with axatilimab includes receiving intravenous (IV) doses of axatilimab every 2 weeks

Treatment groups

No treatment groups listed

Trial outcomes

This trial has no outcomes listed.

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Incyte Corporation

Lead sponsor

Source ClinicalTrials.gov

Apply now